Showing results (21-30 of 112) with videos related to

Sort By:
Pageof 12
Frontiers in Oncology|June 5, 2023
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stageJonathan W Goldman, Lynette M Sholl, Sanja Dacic, et al.
Future Oncology (London, England)|August 11, 2022
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancerMasahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, et al.
Scientific Reports|February 9, 2018
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancerManjima Dhar, Jessica Wong, James Che, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 TrialXiuning Le, Robin Cornelissen, Marina Garassino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced CancerLee S Rosen, Jonathan W Goldman, Alain P Algazi, et al.
Expert Review of Anticancer Therapy|June 28, 2021
The evolution of cyclin dependent kinase inhibitors in the treatment of cancerKomal Jhaveri, Howard A Burris Rd, Timothy A Yap, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic TreatmentTimothy J Williamson, Alyssa K Choi, Julie C Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancerZorawar S Noor, Jonathan W Goldman, William E Lawler, et al.
BMC Cancer|March 28, 2013
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignanciesJonathan W Goldman, Robert N Raju, Gregory A Gordon, et al.
Radiology|December 13, 2017
Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung CancerEmily B Tsai, Kelsey Pomykala, Kathleen Ruchalski, et al.
Pageof 12